Rare disease news

FDA approvals, research breakthroughs, clinical trials, and advocacy updates

Curated and summarized by AI for patients and caregivers

🔍
AllDrug approvalsClinical trialsResearchGrants & fundingAdvocacy & policyPipeline
Show:All newsBreaking onlyImportant & breaking
Date:7 days30 days90 daysAll time

2 articles from the last 30 days matching "Factor VIII"

ResearchRSSToday

Real-world study backs safety of Hemlibra for acquired hemophilia A

A study in Japan found that Hemlibra, a medicine used to treat acquired hemophilia A (a rare bleeding disorder that develops later in life), appears to be safe when used alongside other medications that suppress the immune system. Acquired hemophilia A is different from the hemophilia people are born with—it happens when the body mistakenly attacks its own clotting proteins. This is the first real-world evidence supporting Hemlibra's safety for this condition in actual patients.

WHY IT MATTERSIf you have acquired hemophilia A in Japan or are considering treatment options, this study suggests Hemlibra may be a safe addition to your treatment plan, though you should discuss this with your hematologist to see if it's right for your specific situation.
💬 Ask your doctoracquired hemophilia A
Clinical trialRSSMay 8

Denecimig excels at reducing bleeds in hemophilia A patients: Study

A new medicine called denecimig (Mim8) was tested in a study called FRONTIER2 and worked better than current treatments at stopping bleeding episodes in people with hemophilia A. The medicine was given either once a month or once a week, and it worked well for both adults and teenagers 12 years and older, even for patients whose bodies have developed resistance to other treatments.

WHY IT MATTERSIf denecimig gains approval, hemophilia A patients—especially those with inhibitors who have limited treatment options—could switch to a once-monthly injection that reduces bleeds more effectively than their current preventive regimens.
💬 Ask your doctorhemophilia Ahemophilia A with inhibitors

Get personalized rare disease news

Follow your conditions to see news about the diseases that matter to you — FDA approvals, trial openings, and research breakthroughs.

Create free account →Browse diseases